Targets › TXNIP
1 program from 1 company in 2 trials: 2 Phase 1; Metabolic and endocrine, Other; next expected readout Dec 2026.
May act as an oxidative stress mediator by inhibiting thioredoxin activity or by limiting its bioavailability. Interacts with COPS5 and restores COPS5-induced suppression of CDKN1B stability, blocking the COPS5-mediated translocation of CDKN1B from the nucleus to the cytoplasm (By similarity). (UniProt, Q9H3M7)
Open in Phaseline: the race on TXNIP, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| TIXiMED | TIX100 thioredoxin-interacting protein (TXNIP) inhibitor | TXNIP | Phase 1 | Healthy; Health Adult Subjects | Dec 2026 |
Healthy (1) Health Adult Subjects (1)
small molecule (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.